LIPOCINE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. - LPCN

NEW ORLEANS, Feb. 16, 2018

On June 29, 2016, the Company revealed that the FDA had denied approval of the Company's lead drug product candidate, TLANDO ("LPCN 1021"), a testosterone replacement therapy drug.  According to the Complete Response Letter issued by the FDA, the denial was based on the determination that the dosing scheme used in the Phase 3 trial was "significantly different" from the scheme proposed for real world clinical practice, leading to a finding of "deficiencies related to the dosing algorithm for the label." Throughout the Phase 3 testing process, the Company had repeatedly touted the positive efficacy and safety results of LPCN 1021 in press releases and public filings without revealing the discrepancies in the dosing schemes and the resulting risk of denial of its leading product candidate.

Thereafter, the Company and certain executives were sued in a securities class action lawsuit, for failing to disclose material information, violating federal securities laws. Recently, the Company's motion to dismiss was denied, allowing the case to proceed and days later, the parties announced their agreement to settle the case. 

KSF's investigation focuses on whether Lipocine's officers and/or directors breached their fiduciary duties to Lipocine's shareholders or otherwise violated state or federal laws. 

If you have information that would assist KSF in its investigation, or have been a long-term holder of Lipocine shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-lpcn/ to learn more.

About Kahn Swick & Foti, LLC